Amgen agrees deal to commercialise biosimilars in Japan with Daiichi Sankyo
pharmafile | July 14, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Amgen, Daiichi Sankyo, Japan, biosimilars
Amgen (NASDAQ: AMGN) has agreed a deal with Daiichi Sankyo (TSE: 4568) that will see the pair commercialise nine biosimilars in Japan.
Among the nine are several biosimilars in late-stage development, including Humira (adalimumab), Herceptin (trastuzumab) and Avastin (bevacizumab).
Amgen will manage the development and manufacturing of the biosimilars while Daiichi Sankyo will file for marketing approval and take control of the distribution and commercialisation in Japan. Amgen will retain a limited right to co-promote the products.
No financial details of the agreement were disclosed.
Scott Foraker, vice president and general manager of biosimilars at Amgen, says: “Amgen is excited to collaborate with Daiichi Sankyo as we seek to drive adoption and build confidence in biosimilars as a means of enhancing patient access to more affordable therapeutic options worldwide.”
Biosimilars have been a hot topic for the company in recent weeks. While there was encouraging news as the FDA recommended its version of Humira by 26-0, a big win for Novartis’s biosimilar version of their blockbuster drug Enbrel (etanercept) remains a cause for concern for the company.
Sean Murray
Related Content
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …
Amgen opens new biomanufacturing facility in Ohio, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …